PROCEPT BioRobotics Corp (PRCT) stock
PRCTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/3051% below fair value
$23.51+0.17 (+0.73%)
Close on Nov 12, 2026Market cap $1.35BP/E –Yield –
PROCEPT BioRobotics total assets
Total assets on the balance sheet at the end of each period.
PROCEPT BioRobotics's total assets was $473.76M at Sep 30, 2026. For fiscal 2025 it was $508.08M, down 4.9% from the year before. The highest annual figure on record is $534.02M in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $508.08M | -4.9% |
| FY2024 | Dec 31, 2024 | $534.02M | +31.9% |
| FY2023 | Dec 31, 2023 | $404.72M | +30.8% |
| FY2022 | Dec 31, 2022 | $309.33M | -8.2% |
| FY2021 | Dec 31, 2021 | $337.02M | +167.5% |
| FY2020 | Dec 31, 2020 | $125.97M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $473.76M | -7.4% |
| Q2 FY2026 | Jun 30, 2026 | $479.35M | -6.6% |
| Q1 FY2026 | Mar 31, 2026 | $487.06M | -6.2% |
| Q4 FY2025 | Dec 31, 2025 | $508.08M | -4.9% |
| Q3 FY2025 | Sep 30, 2025 | $511.54M | +36.7% |
| Q2 FY2025 | Jun 30, 2025 | $513.05M | +37.1% |
| Q1 FY2025 | Mar 31, 2025 | $519.38M | +35.6% |
| Q4 FY2024 | Dec 31, 2024 | $534.02M | +31.9% |
| Q3 FY2024 | Sep 30, 2024 | $374.14M | -11.2% |
| Q2 FY2024 | Jun 30, 2024 | $374.35M | +37.4% |
| Q1 FY2024 | Mar 31, 2024 | $382.90M | +34.6% |
| Q4 FY2023 | Dec 31, 2023 | $404.72M | +30.8% |
| Q3 FY2023 | Sep 30, 2023 | $421.13M | +30.0% |
| Q2 FY2023 | Jun 30, 2023 | $272.45M | -12.4% |
| Q1 FY2023 | Mar 31, 2023 | $284.46M | -11.4% |
| Q4 FY2022 | Dec 31, 2022 | $309.33M | -8.2% |
| Q3 FY2022 | Sep 30, 2022 | $324.04M | -7.8% |
| Q2 FY2022 | Jun 30, 2022 | $310.93M | +146.8% |
| Q1 FY2022 | Mar 31, 2022 | $320.91M | – |
| Q4 FY2021 | Dec 31, 2021 | $337.02M | – |
| Q3 FY2021 | Sep 30, 2021 | $351.46M | – |
| Q4 FY2020 | Dec 31, 2020 | $125.97M | – |
See a number that looks wrong?